CARL B. LAUTER, M.D., F.A.C.P.
To the editor: Recent studies have attempted to delineate factors predictive of the outcome in patients with cryptococcal meningitis (1). Diamond and Bennett (2) have presented information that a cryptococcal antigen titer (latex agglutination method) in serum or cerebrospinal fluid (CSF) ≥ 8 at the end of therapy correlated with treatment failure. A latex agglutination cryptococcal antigen test is now available commercially (Crypto-LA Kit®, IBL Laboratories, Inc., Rockville, Maryland) and hence specimens for antigen testing may not have to be submitted to the reference laboratories of the Center for Disease Control or the state health department laboratories. We have been
LAUTER CB. Commercial Test Sensitivity to Cryptococcal Antigen. Ann Intern Med. ;86:240. doi: 10.7326/0003-4819-86-2-240_1
Download citation file:
Published: Ann Intern Med. 1977;86(2):240.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use